{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T01:24:07Z","timestamp":1769649847836,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>To evaluate patterns of primary prophylactic (PP) granulocyte colony\u2013stimulating factor (G-CSF) use following chemotherapy by cancer type and febrile neutropenia (FN) risk.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Using a commercial administrative database, we identified adult patients diagnosed with breast, colorectal, lung, ovarian cancer, or non-Hodgkin lymphoma (NHL) who initiated chemotherapy with high risk (HR) or intermediate risk (IR) for FN between January 1, 2013, and August 31, 2017. We describe use of PP-G-CSF, proportion completing all their cycles with pegfilgrastim, timing of pegfilgrastim, and duration of short-acting G-CSF.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among 22,868 patients (breast 11,513; colorectal 3765; lung 4273; ovarian 1287; and NHL 2030), 36.8% received HR and 63.2% received IR (64.4% of whom had \u2265\u20091 risk factor [RF] for FN). Proportions of patients receiving PP-G-CSF in the first cycle were 76.1%, 28.2%, and 26.4% among patients receiving HR, IR, and IR plus \u2265\u20091 RF, respectively. Among breast cancer patients receiving HR regimens and initiating PP-pegfilgrastim, 60.4% (95% confidence interval [CI] 57.2\u201363.6%) initiating via on-body injector (OBI) and 51.9% (95% CI 48.0\u201355.8%) initiating via prefilled syringe (PFS) completed all their cycles with OBI and PFS, respectively. Among all cycles with PP-PFS, 8.5% received PFS on the same day as chemotherapy completion. Mean administrations\/cycle were 3.2 (standard deviation [SD] 2.3) for filgrastim, 3.0 (SD 1.6) for filgrastim-sndz, and 4.3 (SD 2.5) for tbo-filgrastim.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>There is under- and mistimed use of PP-G-CSF among patients at HR for FN. Novel pegfilgrastim delivery devices could help breast cancer patients at HR for FN complete all their cycles with timely prophylaxis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00520-020-05295-2","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T02:02:26Z","timestamp":1578621746000},"page":"4413-4424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Patterns of granulocyte colony\u2013stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-5349","authenticated-orcid":false,"given":"Prasad L.","family":"Gawade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Belani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Kelsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"5295_CR1","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455\u20132465","journal-title":"N Engl J Med"},{"key":"5295_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379:64\u201373","journal-title":"N Engl J Med"},{"key":"5295_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Fo\u00e0 R, Bassan R, Arslan \u00d6, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Br\u00fcggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836\u2013847","journal-title":"N Engl J Med"},{"key":"5295_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","volume":"4","author":"J Marquart","year":"2018","unstructured":"Marquart J, Chen EY, Prasad V (2018) Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol 4:1093\u20131098","journal-title":"JAMA Oncol"},{"key":"5295_CR5","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s11096-018-0706-9","volume":"40","author":"P Baldo","year":"2018","unstructured":"Baldo P, Fornasier G, Ciolfi L, Sartor I, Francescon S (2018) Pharmacovigilance in oncology. Int J Clin Pharm 40:832\u2013841","journal-title":"Int J Clin Pharm"},{"issue":"Suppl 1","key":"5295_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-200262001-00001","volume":"62","author":"DC Dale","year":"2002","unstructured":"Dale DC (2002) Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 62(Suppl 1):1\u201315","journal-title":"Drugs"},{"key":"5295_CR7","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","volume":"13","author":"E Tai","year":"2017","unstructured":"Tai E, Guy GP, Dunbar A, Richardson LC (2017) Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract 13:e552\u2013e561","journal-title":"J Oncol Pract"},{"key":"5295_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"},{"key":"5295_CR9","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167","journal-title":"J Clin Oncol"},{"key":"5295_CR10","unstructured":"NCCN\u00ae Clinical Practice Guidelines in Oncology. Hematopoietic growth factors. V2.2019. National Comprehensive Cancer Network website. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf. Accessed 4 June 2019"},{"key":"5295_CR11","unstructured":"Centers for Medicare and Medicaid Services. Oncology Care Model. https:\/\/innovation.cms.gov\/initiatives\/oncology-care\/. Accessed 4 June 2019"},{"key":"5295_CR12","unstructured":"Food and Drug Administration. Filgrastim-sndz [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125553lbl.pdf. Accessed 4 June 2019"},{"key":"5295_CR13","unstructured":"Food and Drug Administration. Filgrastim-aafi [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761080s000lbl.pdf. Accessed 4 June 2019"},{"key":"5295_CR14","unstructured":"Food and Drug Administration. Tbo-filgrastim [prescribing information]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125294s0000lbl.pdf. Accessed 4 June 2019"},{"key":"5295_CR15","unstructured":"Food and Drug Administration. Pegfilgrastim-jmdb [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761075s000lbl.pdf. Accessed 4 June 2019"},{"key":"5295_CR16","unstructured":"Food and Drug Administration. Pegfilgrastim-cbqv [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761039s000lbl.pdf. Accessed 4 June 2019"},{"key":"5295_CR17","unstructured":"Food and Drug Administration. Pegfilgrastim [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125031s180lbl.pdf. Accessed 4 June 2019"},{"key":"5295_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/9781119959946.ch13","volume-title":"Pharmacoepidemiology","author":"J Seeger","year":"2012","unstructured":"Seeger J, Daniel GW (2012) PART III sources of data for pharmacoepidemiologic studies. Commercial insurance databases. In: Storm BL, Kimmel SE, Hennessy S (eds) Pharmacoepidemiology. Wiley-Blackwell, Hoboken, pp 189\u2013208"},{"key":"5295_CR19","unstructured":"Optum\u2122 Optum Clinformatics Data Mart. https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/Clinformatics_for_Data_Mart.pdf. Accessed 10 October 2018"},{"key":"5295_CR20","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.6004\/jnccn.2017.0175","volume":"15","author":"J Crawford","year":"2017","unstructured":"Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L (2017) Myeloid growth factors, Version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15:1520\u20131541","journal-title":"J Natl Compr Cancer Netw"},{"key":"5295_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/106286069901400607","volume":"14","author":"PL Hebert","year":"1999","unstructured":"Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM (1999) Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14:270\u2013277","journal-title":"Am J Med Qual"},{"key":"5295_CR22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676\u2013682","journal-title":"Am J Epidemiol"},{"key":"5295_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","volume":"17","author":"CN Klabunde","year":"2007","unstructured":"Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D (2007) A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17:584\u2013590","journal-title":"Ann Epidemiol"},{"key":"5295_CR24","first-page":"678","volume":"16","author":"SD Ramsey","year":"2010","unstructured":"Ramsey SD, McCune JS, Blough DK, McDermott CL, Clarke L, Malin JL, Sullivan SD (2010) Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care 16:678\u2013686","journal-title":"Am J Manag Care"},{"key":"5295_CR25","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s00520-017-3720-x","volume":"25","author":"R Sosa","year":"2017","unstructured":"Sosa R, Li S, Molony JT, Liu J, Stryker S, Collins AJ (2017) Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database. Support Care Cancer 25:3123\u20133132","journal-title":"Support Care Cancer"},{"key":"5295_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00520-017-3863-9","volume":"26","author":"RK Goyal","year":"2018","unstructured":"Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA (2018) Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Support Care Cancer 26:539\u2013548","journal-title":"Support Care Cancer"},{"key":"5295_CR27","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.2011.39.9980","volume":"30","author":"TJ Smith","year":"2012","unstructured":"Smith TJ, Hillner BE (2012) A way forward on the medically appropriate use of white cell growth factors. J Clin Oncol 30:1584\u20131587","journal-title":"J Clin Oncol"},{"key":"5295_CR28","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/1078155218799859","volume":"25","author":"H Baig","year":"2018","unstructured":"Baig H, Somlo B, Eisen M, Stryker S, Bensink M, Morrow PK (2018) Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level. J Oncol Pharm Pract 25:1576. https:\/\/doi.org\/10.1177\/1078155218799859","journal-title":"J Oncol Pharm Pract"},{"key":"5295_CR29","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO, Oncology ASoC (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212","journal-title":"J Clin Oncol"},{"key":"5295_CR30","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1200\/JCO.2012.44.6229","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 31:4290\u20134296","journal-title":"J Clin Oncol"},{"key":"5295_CR31","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1080\/03007995.2017.1386638","volume":"33","author":"D Weycker","year":"2017","unstructured":"Weycker D, Bensink M, Wu H, Doroff R, Chandler D (2017) Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015. Curr Med Res Opin 33:2115\u20132120","journal-title":"Curr Med Res Opin"},{"key":"5295_CR32","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00520-015-3036-7","volume":"24","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Figueredo J, Barron R, Tzivelekis S, Hagiwara M (2016) Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer 24:2309\u20132316","journal-title":"Support Care Cancer"},{"key":"5295_CR33","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1080\/03007995.2017.1386858","volume":"33","author":"D Weycker","year":"2017","unstructured":"Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D (2017) Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin 33:2107\u20132113","journal-title":"Curr Med Res Opin"},{"key":"5295_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JOP.091094","volume":"6","author":"HA Burris","year":"2010","unstructured":"Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin\u2019s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 6:133\u2013140","journal-title":"J Oncol Pract"},{"key":"5295_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","volume":"1","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1:23\u201335","journal-title":"Support Cancer Ther"},{"key":"5295_CR36","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1001\/jamaoncol.2018.5090","volume":"4","author":"X Chen","year":"2018","unstructured":"Chen X, Agiro A, Barron J, Debono D, Fisch M (2018) Early adoption of biosimilar growth factors in supportive cancer care. JAMA Oncol 4:1779\u20131781","journal-title":"JAMA Oncol"},{"key":"5295_CR37","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jama.2018.9014","volume":"320","author":"S Kozlowski","year":"2018","unstructured":"Kozlowski S, Birger N, Brereton S, McKean SJ, Wernecke M, Christl L, Kelman JA (2018) Uptake of the biologic filgrastim and its biosimilar product among the Medicare population uptake of the biologic filgrastim and its biosimilar among the Medicare population letters. JAMA 320:929\u2013931","journal-title":"JAMA"},{"key":"5295_CR38","first-page":"976","volume":"24","author":"LS Schwartzberg","year":"2018","unstructured":"Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, DeLeon A, Elliott C, Korrer S (2018) Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy. J Manag Care Spec Pharm 24:976\u2013984","journal-title":"J Manag Care Spec Pharm"},{"key":"5295_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2407-13-11","volume":"13","author":"A Naeim","year":"2013","unstructured":"Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R (2013) Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 13:11","journal-title":"BMC Cancer"},{"key":"5295_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20:727\u2013731","journal-title":"J Clin Oncol"},{"key":"5295_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, Group IPS (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29\u201335","journal-title":"Ann Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-020-05295-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T03:54:38Z","timestamp":1610164478000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-020-05295-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5295"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05295-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"assertion":[{"value":"21 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Prasad L. Gawade, Brian D. Bradbury, Rajesh Belani, and Michael A. Kelsh are employees of and own stock in Amgen Inc. Nancy Smith was an employee of DOCS Global and was contracted to work with Amgen Inc. during the period of this study. Shuling Li is an employee of Chronic Disease Research Group, Hennepin Healthcare Research Institute, which has received project funding from Amgen Inc. David Henry has received honoraria for serving on an advisory board for Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Formal consent was not required as the article does not contain any studies involving human participants performed by any of the authors..","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}